查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1798778

全球色素減退治療市場的成長、規模和趨勢分析：按治療類型、適應症和地區的展望、競爭策略、預測（至2034年）

Global Hypopigmentation Disorder Treatment Market Growth, Size, Trends Analysis- By Treatment Type, By Disease Indication - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 244 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到2034年，全球色素減退治療市場規模將達到 61.1億美元，預測期內的年複合成長率為 6.36%。

色素減退症的治療著重於解決以黑色素（決定膚色的色素）減少或缺失為特徵的疾病。常見疾病包括白斑症、白化症和發炎後色素減退症。治療的目標是恢復色素沉著，改善外觀，並提高整體生活品質。

阻礙因素：色素減退治療市場面臨許多障礙，可能會限制其成長。其中一大挑戰是缺乏根治性方案，因為許多治療方法目的是控制症狀，而非提供永久性的緩解。患者對局部固醇和照光治療等治療方法的反應差異很大，難以確保療效的一致性。

本報告調查了全球色素減退治療市場，並提供了市場概況、市場影響因素和市場機會分析、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局以及主要企業的概況。

目錄

第1章 引言

第2章 調查方法

第3章 執行摘要

第4章 市場動態

  • 促進因素、阻礙因素、機會與挑戰分析

第5章 市場變數與展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 熱圖分析

第6章 競爭態勢

  • 製造地、銷售區域、產品類型分佈
  • 併購、合作夥伴關係、產品發布和合作

第7章 全球色素減退治療市場

  • 藥物
    • 皮質類固醇
    • 促黑素細胞激素
    • 其他
  • 依治療
    • 雷射治療
    • 照光治療
    • 微晶換膚
    • 其他
  • 依最終用戶
    • 醫院
    • 皮膚科診所
    • 美容中心
  • 其他

第8章 全球色素減退治療市場（依疾病）

  • 白斑
  • 白化病
  • 其他

第9章 全球色素減退治療市場

  • 市場規模和市場佔有率

第10章 全球色素減退治療市場（依地區）

  • 亞太地區
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 埃及
    • 摩洛哥
    • 奈及利亞
    • 其他
  • 北美洲
    • 加拿大
    • 墨西哥
    • 美國
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他

第11章 公司簡介

  • AbbVie Inc.
  • Aclaris Therapeutics, Inc.
  • Bayer AG
  • Candela Corporation
  • Galderma
  • Incyte
  • Novartis AG
  • Pfizer Inc.
  • Pierre Fabre group
  • Shiseido Company Limited
  • 其他

第12章 結論

第13章 簡稱表

第14章 參考鏈接

簡介目錄
Product Code: HLCA25212

Hypopigmentation Disorder Treatment Market Introduction and Overview

According to SPER market research, 'Global Hypopigmentation Disorder Treatment Market Size- By Treatment Type, By Disease Indication - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Hypopigmentation Disorder Treatment Market is predicted to reach 6.11 billion by 2034 with a CAGR 6.36%.

Hypopigmentation disorder treatment focuses on addressing conditions marked by a reduction or loss of melanin, the pigment responsible for skin color. Common conditions include vitiligo, albinism, and post-inflammatory hypopigmentation. The goal of treatment is to restore pigmentation, enhance appearance, and improve overall quality of life.

Restraints: The hypopigmentation disorder treatment market encounters several obstacles that may restrict its growth. A key challenge is the scarcity of curative options, as most treatments aim to manage symptoms rather than deliver lasting results. Patient responses to therapies like topical corticosteroids and phototherapy can vary widely, making it difficult to ensure consistent effectiveness.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Treatment Type, By Disease Indication

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

AbbVie Inc., Aclaris Therapeutics, Inc., Bayer AG, Candela Corporation, Galderma, Incyte, Novartis AG, Pfizer Inc., Pierre Fabre Group, Shiseido Company Limited.

Global Hypopigmentation Disorder Treatment Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Hypopigmentation Disorder Treatment Market is segmented as; Drugs, Procedures.

By Disease Indication: Based on the Disease Indication, Global Hypopigmentation Disorder Treatment Market is segmented as; Vitiligo, Albinism, Other disease indications.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.

Table of Contents

1.Introduction

  • 1.1.Scope of the report
  • 1.2.Market segment analysis

2.Research Methodology

  • 2.1.Research data source
    • 2.1.1.Secondary Data
    • 2.1.2.Primary Data
    • 2.1.3.SPERs internal database
    • 2.1.4.Premium insight from KOLs
  • 2.2.Market size estimation
    • 2.2.1.Top-down and Bottom-up approach
  • 2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

  • 4.1.Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1.Drivers
    • 4.1.2.Restraints
    • 4.1.3.Opportunities
    • 4.1.4.Challenges

5.Market variable and outlook

  • 5.1.SWOT Analysis
    • 5.1.1.Strengths
    • 5.1.2.Weaknesses
    • 5.1.3.Opportunities
    • 5.1.4.Threats
  • 5.2.PESTEL Analysis
    • 5.2.1.Political Landscape
    • 5.2.2.Economic Landscape
    • 5.2.3.Social Landscape
    • 5.2.4.Technological Landscape
    • 5.2.5.Environmental Landscape
    • 5.2.6.Legal Landscape
  • 5.3.PORTERs Five Forces
    • 5.3.1.Bargaining power of suppliers
    • 5.3.2.Bargaining power of buyers
    • 5.3.3.Threat of Substitute
    • 5.3.4.Threat of new entrant
    • 5.3.5.Competitive rivalry
  • 5.4.Heat Map Analysis

6.Competitive Landscape

  • 6.1.Global Hypopigmentation Disorder Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Hypopigmentation Disorder Treatment Market

7.Global Hypopigmentation Disorder Treatment Market, (USD Million) 2021-2034

  • 7.1.Drugs
    • 7.1.1.Corticosteroids
    • 7.1.2.Melanocyte-stimulating hormone
    • 7.1.3.Other drugs
  • 7.2.Procedures
    • 7.2.1.Laser treatment
    • 7.2.2.Phototherapy
    • 7.2.3.Microdermabrasion
    • 7.2.4.Other procedures
  • 7.3.By end-user
    • 7.3.1.Hospitals
    • 7.3.2.Dermatology clinics
    • 7.3.3.Aesthetic centers
  • 7.4.Other end-users

8.Global Hypopigmentation Disorder Treatment Market, By Disease Indication, (USD Million) 2021-2034

  • 8.1.Vitiligo
  • 8.2.Albinism
  • 8.3.Other disease indications

9.Global Hypopigmentation Disorder Treatment Market, (USD Million) 2021-2034

  • 9.1.Global Hypopigmentation Disorder Treatment Market Size and Market Share

10.Global Hypopigmentation Disorder Treatment Market, By Region, 2021-2034 (USD Million)

  • 10.1.Asia-Pacific
    • 10.1.1.Australia
    • 10.1.2.China
    • 10.1.3.India
    • 10.1.4.Japan
    • 10.1.5.South Korea
    • 10.1.6.Rest of Asia-Pacific
  • 10.2.Europe
    • 10.2.1.France
    • 10.2.2.Germany
    • 10.2.3.Italy
    • 10.2.4.Spain
    • 10.2.5.United Kingdom
    • 10.2.6.Rest of Europe
  • 10.3.Middle East and Africa
    • 10.3.1.Kingdom of Saudi Arabia
    • 10.3.2.United Arab Emirates
    • 10.3.3.Qatar
    • 10.3.4.South Africa
    • 10.3.5.Egypt
    • 10.3.6.Morocco
    • 10.3.7.Nigeria
    • 10.3.8.Rest of Middle-East and Africa
  • 10.4.North America
    • 10.4.1.Canada
    • 10.4.2.Mexico
    • 10.4.3.United States
  • 10.5.Latin America
    • 10.5.1.Argentina
    • 10.5.2.Brazil
    • 10.5.3.Rest of Latin America

11.Company Profile

  • 11.1.AbbVie Inc.
    • 11.1.1.Company details
    • 11.1.2.Financial outlook
    • 11.1.3.Product summary
    • 11.1.4.Recent developments
  • 11.2.Aclaris Therapeutics, Inc.
    • 11.2.1.Company details
    • 11.2.2.Financial outlook
    • 11.2.3.Product summary
    • 11.2.4.Recent developments
  • 11.3.Bayer AG
    • 11.3.1.Company details
    • 11.3.2.Financial outlook
    • 11.3.3.Product summary
    • 11.3.4.Recent developments
  • 11.4.Candela Corporation
    • 11.4.1.Company details
    • 11.4.2.Financial outlook
    • 11.4.3.Product summary
    • 11.4.4.Recent developments
  • 11.5.Galderma
    • 11.5.1.Company details
    • 11.5.2.Financial outlook
    • 11.5.3.Product summary
    • 11.5.4.Recent developments
  • 11.6.Incyte
    • 11.6.1.Company details
    • 11.6.2.Financial outlook
    • 11.6.3.Product summary
    • 11.6.4.Recent developments
  • 11.7.Novartis AG
    • 11.7.1.Company details
    • 11.7.2.Financial outlook
    • 11.7.3.Product summary
    • 11.7.4.Recent developments
  • 11.8.Pfizer Inc.
    • 11.8.1.Company details
    • 11.8.2.Financial outlook
    • 11.8.3.Product summary
    • 11.8.4.Recent developments
  • 11.9.Pierre Fabre group
    • 11.9.1.Company details
    • 11.9.2.Financial outlook
    • 11.9.3.Product summary
    • 11.9.4.Recent developments
  • 11.10. Shiseido Company Limited
    • 11.10.1.Company details
    • 11.10.2.Financial outlook
    • 11.10.3.Product summary
    • 11.10.4.Recent developments
  • 11.11.Others

12.Conclusion

13.List of Abbreviations

14.Reference Links